Posted by Michael Wonder on 11 Jul 2017
Institute for Clinical and Economic Review posts draft scoping document on voretigene neparvovec, first gene therapy submitted for FDA approval
10 July 2017 - Report expected to review clinical effectiveness, value of the therapy; Scoping Document will be open to public comment until 31 July 2017.
The Institute for Clinical and Economic Review has posted a draft scoping document that will shape an upcoming report on voretigene neparvovec (Spark Therapeutics), a gene therapy currently under FDA review for people with vision loss associated with biallelic RPE65-mediated retinal disease.
The draft scoping document will be open to public comment for three weeks until 31 July 2017.
